<--- Back to Details
First PageDocument Content
Clinical medicine / Medicine / Antineoplastic drugs / Breakthrough therapy / Pharmacology / Bristol-Myers Squibb / Monoclonal antibodies / Immune system / Programmed cell death protein 1 / Nivolumab / Pharmac / Pembrolizumab
Date: 2016-05-25 01:37:50
Clinical medicine
Medicine
Antineoplastic drugs
Breakthrough therapy
Pharmacology
Bristol-Myers Squibb
Monoclonal antibodies
Immune system
Programmed cell death protein 1
Nivolumab
Pharmac
Pembrolizumab

24 MayDanae Staples-Moon Therapeutic Group Manager PHARMAC PO Box

Add to Reading List

Source URL: www.nzma.org.nz

Download Document from Source Website

File Size: 204,92 KB

Share Document on Facebook

Similar Documents

PDF Document

DocID: 1xvUb - View Document

PDF Document

DocID: 1xc8R - View Document

Institute of Pharmacology www.pki.unibe.ch Introduction Prof. Dr. Dr. Stephan von Gunten MD PhD MME

Institute of Pharmacology www.pki.unibe.ch Introduction Prof. Dr. Dr. Stephan von Gunten MD PhD MME

DocID: 1vqsj - View Document

Jansone et al.: Intrinsic Activity, 2017; 5 (Suppl.2):A1.6 doi:IA.5.S2-A1.6 published online: 16 October 2017 2nd International Conference in Pharmacology: From Cellular Processes to Drug Targets Rīga, Latvia

Jansone et al.: Intrinsic Activity, 2017; 5 (Suppl.2):A1.6 doi:IA.5.S2-A1.6 published online: 16 October 2017 2nd International Conference in Pharmacology: From Cellular Processes to Drug Targets Rīga, Latvia

DocID: 1vlJU - View Document

Human cells  Notable for research in: -Medecine: Diseases and cancers -Cell Biology -Pharmacology

Human cells Notable for research in: -Medecine: Diseases and cancers -Cell Biology -Pharmacology

DocID: 1vk1K - View Document